US EditionPublished • loading... • Updated
Gilead to buy Arcellx in nearly $8B deal
Summary by STAT
4 Articles
4 Articles
Gilead to buy US biotech Arcellx for up to $7.8 billion
By Stuart Biggs, Bloomberg Gilead Sciences Inc. agreed to buy US cancer-focused biotech Arcellx Inc. for as much as $7.8 billion as it seeks to boost its drug pipeline. Gilead, which owns 11.5% of Arcellx’s outstanding stock, will pay $115 per share in cash, with a contingent payment of $5 per share dependent on future sales, it said Monday. The price is almost double Arcellx’s Friday closing price. Related Articles Bay Area tech w…
·San Jose, United States
Read Full Article
The US pharmaceutical company Gilead Sciences acquires the biotech company Arcellx for 7.8 billion dollars. With the deal, Gilead controls the promising cancer therapy anito-cel.
·Düsseldorf, Germany
Read Full Article
Coverage Details
Total News Sources4
Leaning Left1Leaning Right1Center1Last UpdatedBias Distribution34% Left, 33% Center, 33% Right
Bias Distribution
- 34% of the sources lean Left, 33% of the sources are Center, 33% of the sources lean Right
34% Left
L 34%
C 33%
R 33%
Factuality
To view factuality data please Upgrade to Premium
